Two awards programmes for start-up innovators came together on 21 February 2012 in Brussels: The first start-up awards offered by the European Institute of Innovation and Technology (EIT), and the fourth annual Academic Enterprise Awards (ACES) offered by the Science|Business Innovation Board. Together, the two programmes bring together 21 young entrepreneurs from across Europe, to compete for seven awards.
Alan Leshner, CEO of the American Association for the Advancement of Science, caused a stir at February’s EU ministerial conference in Copenhagen, with a hard-hitting speech on the state of US science. America's scientific eminence, 'is at risk' he said.
A private equity firm is to raise the largest specialist fund in the world dedicated to commercialising university R&D. The money will be invested in partnership with three of the UK’s leading research universities
This ACES 2011 yearbook celebrates the achievements of Europe’s academic entrepreneurs, and charts Europe’s progress in building a new culture of innovation on campus.
The US patent office has released studies on international patenting and prior user defence, with other reports looking at the US patents scene to follow
Hard-pressed healthcare systems can no longer pay premium prices for new drugs. The consequence will be less innovation in Europe says Andrew Witty, CEO of GlaxoSmithKline.
25 countries have agreed to back a single European research plan in neurodegenerative diseases. This is a defining moment for coordinated research says the Commissioner
The European Commission proposes to unite national funding agencies in ‘pacts’ to complete the European Research Area (ERA) by 2014 deadline - without further legislation
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.